Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
4.01
Nov 17 • 3:59 PM ET Dollar change+0.43 Percentage change(12.15%)
Aftermarket Close
3.97
Aftermarket • 5:42 PM ET Dollar change-0.04 Percentage change(-1.12%)
Index
RUT
Market Cap
388.37M
Enterprise Value
299.12M
Income
-77.92M
Sales
0.00M
Book/sh
0.89
Cash/sh
0.93
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
58
IPO
May 08, 2012
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
4.52
P/C
4.32
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
9.92
Current Ratio
9.92
Debt/Eq
0.01
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-0.75
EPS next Y
-0.49
EPS next Q
-0.17
EPS this Y
9.33%
EPS next Y
27.81%
EPS next 5Y
-
EPS past 3/5Y
9.63% 22.81%
Sales past 3/5Y
- -
EPS Y/Y TTM
19.53%
Sales Y/Y TTM
-
EPS Q/Q
-0.51%
Sales Q/Q
-
Insider Own
13.96%
Insider Trans
0.00%
Inst Own
94.25%
Inst Trans
5.18%
ROA
-61.19%
ROE
-66.85%
ROIC
-90.55%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
2.84%
SMA50
-0.68%
SMA200
2.19%
Trades
Shs Outstand
96.72M
Shs Float
83.22M
52W High
11.16 -64.04%
52W Low
1.07 275.23%
Volatility
11.30% 8.46%
ATR (14)
0.37
RSI (14)
51.36
Beta
0.65
Rel Volume
1.77
Avg Volume
1.63M
Volume
2,888,370
Perf Week
-0.12%
Perf Month
8.51%
Perf Quarter
-14.94%
Perf Half Y
29.52%
Perf YTD
70.13%
Perf Year
-60.71%
Perf 3Y
390.95%
Perf 5Y
-31.37%
Perf 10Y
-94.26%
Prev Close
3.58
Price
4.01
Change %
12.15%
Consensus
Strong Buy
Avg. Price Target
$10.80
Implied Upside
+169.0%
Analysts12incl. previous ratings
Rating Distribution12 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 06, 2026Upgrade
CCantor Fitzgerald
Neutral → Overweight
Sep 30, 2026Initiated
LLake Street
Buy$9+124.2%
Sep 29, 2026Upgrade
CCraig Hallum
Hold → Buy$7+74.3%
Jun 03, 2026Upgrade
CCitizens
Mkt Perform → Mkt Outperform$11+174.0%
Mar 25, 2026Upgrade
WWedbush
Neutral → Outperform$5+24.5%
Dec 11, 2025Downgrade
WWedbush
Outperform → Neutral$1-75.1%
Dec 11, 2025Downgrade
CCraig Hallum
Buy → Hold$2-50.2%
Dec 11, 2025Downgrade
CCantor Fitzgerald
Overweight → Neutral
Nov 05, 2024Initiated
WWedbush
Outperform$12+198.9%
Aug 27, 2024Initiated
GGuggenheim
Buy$11+174.0%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Evans DaronCFOMar 30 '26Buy2.8510,00028,500414,462Mar 31 04:59 PM
Hogenhuis WladimirDirectorDec 16 '25Buy1.695,6509,548119,675Dec 17 04:14 PM
ROBERTS BRIAN KENNETHChief Medical OfficerDec 16 '25Buy1.7028,00047,600308,352Dec 17 04:13 PM
Evans DaronCFODec 15 '25Buy1.7740,00070,640415,900Dec 15 07:35 PM
Evans DaronCFODec 15 '25Buy1.795,0008,9387,000Dec 15 07:35 PM
Elam Nevan CCEODec 15 '25Buy1.5932,00050,880641,119Dec 15 07:35 PM
Karnawat Sunil RatilalChief Commercial OfficerDec 15 '25Buy1.6212,10019,59971,542Dec 15 07:34 PM
Evans DaronCFODec 09 '25Buy5.0410,54953,167131,900Dec 10 09:11 AM
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its antibody therapy, ersodetug, is designed to treat all forms of hyperinsulinism. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada in March 2010 and is headquartered in Redwood City, CA.
FounderMr. Nevan Charles Elam J.D.
M.S.Mr. Daron G. Evans M.B.A.
Chief Medical OfficerDr. Brian Kenneth Roberts M.D.
Ph.D.Dr. Sunil Karnawat M.B.A.
Senior VP & Head of OperationsMr. Michael R. Deperro